Praxis rises on ulixacaltamide gaining Breakthrough Therapy status
Source: SeekingAlpha
2025-12-29 09:29:05 ET
More on Praxis Precision Medicines
- Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026
- Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET
- Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies Transcript
- Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen
- Praxis Precision Medicines drops after Culper Research short call
Read the full article on Seeking Alpha
For further details see:
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status
Praxis Precision Medicines Inc.
NASDAQ: PRAX
PRAX Trading
7.19% G/L:
$319.25 Last:
168,187 Volume:
$305.79 Open:
PRAX Latest News
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 04, 2026 04:01:00 pm
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2026 01:49:01 pm
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
February 22, 2026 02:36:11 pm
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
PRAX Stock Data
$8,057,264,446
20,105,683
0.7%
83
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
